GnRH Inhibitors and agonists to keep growth plates open and pause puberty

[gazoro]

Gonadotropin-Releasing Hormone (GnRH) analogues are synthetic medications that alter the bodys primary reproductive axis, the Hypothalamic-Pituitary-Gonadal (HPG) axis.

The hypothalamus releases GnRH in pulses to signal the pituitary gland to release Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), which drive the production of testosterone or estrogen. GnRH analogues disrupt this pulsing rhythm in two ways:

• GnRH Agonists (eg Leuprolide, Histrelin): These medications initially stimulate the pituitary gland, causing a temporary 1 to 2 week hormone flare where hormones rise. Over the following weeks, continuous exposure desensitizes and the pituitary receptors, completely shutting down LH and FSH production. They are long acting and typically administered via monthly injections or annual implants.
• GnRH Antagonists (eg, Cetrorelix, Relugolix): These medications act as direct blockers. They bind competitively to the pituitary receptors and cause an immediate hormonal drop within hours, bypassing the initial hormone flare entirely. They are usually short-acting and require daily dosing.

---

​

2. The Height Paradox: Pubertal Extension vs. Growth Velocity

A common hypothesis is that by using a GnRH blocker to stop sex hormones from closing the epiphyseal plates (growth plates), an adolescent can extend their growth window and achieve a taller final adult height.

• Plate Fusion: Estrogen (which is converted from testosterone in biological males) is the specific hormone responsible for the final maturation and hardening (fusion) of growth plates. Blocking GnRH keeps the growth plates open longer.
• Growth Velocity: Growth plates require the synergistic interaction of Human Growth Hormone (hGH) and sex steroids (testosterone or estrogen) to rapidly lengthen bones. Sex hormones act as the primary fuel for the "pubertal growth spurt."

When an adolescent takes a GnRH analogue, they succeed in delaying plate fusion, but they simultaneously remove the hormonal fuel required for rapid growth. The skeleton's growth velocity drops to a extremely slow rate. However, this increase in height, although small, is enough to cause a difference in the final height of the adolescent when he/she reaches adulthood.

---

​

Clinical Scenario	Impact on Final Adult Height	Underlying Physiology
Central Precocious Puberty (Onset < 8–9 years old)	Highly Effective Increase	Prevents growth plates from fusing prematurely in early childhood. Restores a normal timeline so the child can grow to match their peer group.
Normally Timed Puberty (Ages 13–17 without disorder)	Extremely slight increase	The skeleton has already completed its foundational pubertal development. Growth velocity stalls, leading to an identical or slightly taller adult height compared to natural progression.
Combined Therapy (GnRH Blocker + hGH)	Slight Increase	The blocker is used solely to prevent plate fusion while massive daily doses hGH is injected to force bone elongation.

---

​

4. Effects on Skeletal & Facial Development

GnRH blockers operate strictly as a pause button rather than a reversal mechanism. They lock the adolescent's current developmental state in place while preventing further maturation.

Skeletal Dynamics

• Irreversible Changes: Any structural skeletal changes that have already occurred, such as a broadened shoulder frame, a widened pelvic structure, or overall bone length, are permanent and cannot be undone by hormone deprivation.
• Adrenal Variables: Secondary pubertal developments driven by the adrenal glands (adrenarche), including the appearance of pubic hair, pit hair, body odor, and certain types of acne, are independent of the HPG axis and will continue to develop normally despite GnRH blocker use.

Facial Architecture

• Bone Maturation: Facial bones undergo masculinization or feminization under the direct influence of sex steroids. Testosterone promotes the thickening of the jawline, widening of the chin, and prominent development of the brow ridge (supraorbital ridge). Estrogen promotes subtler angular changes. Starting a blocker freezes these bones at their current stage of development, preventing further structural shifts.
• Soft Tissue & Fat Mapping: Estrogen directs soft subcutaneous fat accumulation in the cheeks, yielding a softer, rounded facial profile. Testosterone thickens skin layers and stimulates sebaceous glands.
• Pilosebaceous Units: In individuals with testosterone, terminal hair follicles (beards and mustaches) mature progressively. A GnRH blocker stops new hair follicles from converting into coarse terminal hairs, though any fully developed facial hair will remain.

Although hypothetically, with hormones blocked as of the start of GnRH use, causes the facial development to slow down significantly, the facial development of the adolescent can be altered through habits. This can overturn a lot of recession or underdevelopment of the face through time bought by the GnRH.

However with added hGH, the blocker can keep the growth plates open while the hGH forces the bones to grow. This window can also be used to supplement yourself with all sorts of peptides etc to help with facial and overall development with the time created through the use of GnRH blockers